Loading dashboard...
Loading dashboard...
De-risking decisions with 95.5% predictive accuracy. Stress-test reliability across your specific strategic parameters.
| Clinical Trial | Certified Prospective Prediction | Prediction Validation | Prediction Result | |
|---|---|---|---|---|
Phase 3 | Prediction Index2094 NCTIDNCT06081894 AcronymACACIA-HCM Drug NameAficamten Drug MoAcardiac myosin inhibitor Drug Modalitysmall molecule Drug ClassFirst-In-Class Therapeutic AreaCardiovascular Diseases IndicationSymptomatic Non-Obstructive Hypertrophic Cardiomyopathy (non-obstructive HCM) Human Patients500 SponsorCytokinetics Incorporated TickerCYTK | Prediction Date 16 Nov 2025 Commercial Predictionpartial SUCCESS (commercially maybe sufficient yet moderate clinical benefit in KCCQ CSS numerically-to-slightly superior to metoprolol) Technical PredictionSUCCESS (statistically significant clinical benefit in KCCQ CSS compared with placebo) Timestamped PDFTimestamped PDF Delivered to Clients
Quarter AheadQ1'26 Batch 6 | Readout Date 4 May 2026 Prediction To Readout169 days in advance Readout Data Interpretationaficamten achieved statistically significant 3.0 placebo-adjusted improvement in KCCQ-CSS (p= 0.021) and 0.67 placebo-adjusted improvement in pVO2 (p= 0.003), moderately superior mavacamten as prospectively predicated in No. 1959 (see add'l link below); safe and well-tolerated Press ReleasePress Release Additional Readout DataAdd'l Clinical Benefit Comparison Data | Prediction AccuracyCorrect Prediction Clinical Benefit Conclusionstatistically significant and commercially sufficient (moderately superior to mavacamten) Prediction ClassificationTrue Positive (TP) |
Phase 3 | Prediction Index1959 NCTIDNCT05582395 AcronymODYSSEY-HCM Drug NameMavacamten Drug MoAcardiac myosin inhibitor Drug Modalitysmall molecule Drug ClassFirst-In-Class Therapeutic AreaCardiovascular Diseases Indicationnon-obstructive hypertrophic cardiomyopathy (nHCM) Human Patients580 SponsorBristol-Myers Squibb TickerBMY | Prediction Date 2 Apr 2025 Commercial Predictionpartial SUCCESS (commercially maybe sufficient yet weak clinical benefit in KCCQ moderately inferior to aficamten) Technical Predictionpartial SUCCESS (statistically maybe significant yet weak clinical benefit in KCCQ compared with placebo) Timestamped PDFTimestamped PDF Delivered to Clients
Quarter Ahead Q2'25 Batch 14b | Readout Date 14 Apr 2025 Prediction To Readout12 days in advance Readout Data Interpretationmavacamten failed to meet either the KCCQ-23 CSS or the pVO2 primary endpoints Press ReleasePress Release | Prediction AccuracyCorrect Prediction Clinical Benefit Conclusionstatistically insignificant and commercially insufficient Prediction ClassificationTrue Negative (TN) |
Phase 3 | Prediction Index984 NCTIDNCT02831959 AcronymMETIS Drug NameNovoTTF-200M device Best Standard of Care Drug MoAa device delivering low-intensity; wave-like alternating electric fields to the location of the tumor Drug Modalitymedical device Drug ClassFirst-In-Class Therapeutic AreaNeoplasms IndicationBrain Metastases From Non-small Cell Lung Cancer (NSCLC) Human Patients270 SponsorNovoCure TickerNVCR | Prediction Date 22 Dec 2023 Commercial PredictionFAILURE (commercially insufficient additive clinical benefit) Technical Predictionpartial SUCCESS (statistically significant yet weak additive clinical benefit) Timestamped PDFTimestamped PDF Delivered to Clients
Quarter AheadQ1'24 Batch 12 | Readout Date 27 Mar 2024 Prediction To Readout96 days in advance Readout Data Interpretation21.9month vs 11.3month time to intracranial progression (p=0.016) OS secondary endpoint not met. Press ReleasePress Release | Prediction AccuracyCorrect Prediction Clinical Benefit Conclusionstatistically significant yet commercially insufficient (no OS benefit) Prediction ClassificationTrue Negative (TN) |